Fall of the mutants: T cells targeting BCR-ABL

Premal Lulla; Helen Heslop

doi:10.1182/blood-2016-12-757336

Fall of the mutants: T cells targeting BCR-ABL

Premal Lulla, Helen Heslop

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Abstract

Targeting the tumor-specific junction sequence produced by the BCR-ABL fusion has long been an attractive strategy and, in this issue of Blood, Comoli et al demonstrate, for the first time in humans, clinical benefit with infusions of ^p190BCR-ABL neoantigen-specific T cells to 3 patients with active Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph⁺ ALL).¹.

Original language	English (US)
Pages (from-to)	539-540
Number of pages	2
Journal	Blood
Volume	129
Issue number	5
DOIs	https://doi.org/10.1182/blood-2016-12-757336
State	Published - Feb 2 2017

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2016-12-757336

Cite this

@article{3c818c3d27f942978a9529e624613cc6,

title = "Fall of the mutants: T cells targeting BCR-ABL",

abstract = "Targeting the tumor-specific junction sequence produced by the BCR-ABL fusion has long been an attractive strategy and, in this issue of Blood, Comoli et al demonstrate, for the first time in humans, clinical benefit with infusions of p190BCR-ABL neoantigen-specific T cells to 3 patients with active Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).1.",

author = "Premal Lulla and Helen Heslop",

note = "Publisher Copyright: {\textcopyright} 2017 by The American Society of Hematology.",

year = "2017",

month = feb,

day = "2",

doi = "10.1182/blood-2016-12-757336",

language = "English (US)",

volume = "129",

pages = "539--540",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "5",

}

TY - JOUR

T1 - Fall of the mutants

T2 - T cells targeting BCR-ABL

AU - Lulla, Premal

AU - Heslop, Helen

PY - 2017/2/2

Y1 - 2017/2/2

N2 - Targeting the tumor-specific junction sequence produced by the BCR-ABL fusion has long been an attractive strategy and, in this issue of Blood, Comoli et al demonstrate, for the first time in humans, clinical benefit with infusions of p190BCR-ABL neoantigen-specific T cells to 3 patients with active Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).1.

AB - Targeting the tumor-specific junction sequence produced by the BCR-ABL fusion has long been an attractive strategy and, in this issue of Blood, Comoli et al demonstrate, for the first time in humans, clinical benefit with infusions of p190BCR-ABL neoantigen-specific T cells to 3 patients with active Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).1.

UR - http://www.scopus.com/inward/record.url?scp=85014824993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014824993&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-12-757336

DO - 10.1182/blood-2016-12-757336

M3 - Comment/debate

C2 - 28153834

AN - SCOPUS:85014824993

SN - 0006-4971

VL - 129

SP - 539

EP - 540

JO - Blood

JF - Blood

IS - 5

ER -

Fall of the mutants: T cells targeting BCR-ABL

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this